Learning about dacomitinib for lung cancer treatment
Real-World Treatment Patterns and Clinical Effectiveness of Dacomitinib in Advanced Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Positive in Taiwan
This study is looking to learn about the experiences of patients with advanced non-small cell lung cancer who have been treated with the medication dacomitinib to see how well it works and how safe it is.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Pfizer Industry-sponsored |
| Drugs / interventions | dacomitinib |
| Locations | 1 site (Taipei) |
| Trial ID | NCT06321510 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather information on the experiences of patients with non-small cell lung cancer (NSCLC) who have been treated with dacomitinib, a medication targeting epidermal growth factor receptor (EGFR) mutations. Participants must have advanced NSCLC that could not be controlled and have received dacomitinib as their first-line treatment. The study will assess the safety and effectiveness of dacomitinib based on patient experiences and outcomes. Data will be collected from patients who took dacomitinib until their cancer no longer responded to the treatment.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with advanced NSCLC and EGFR-activating mutations who have previously received dacomitinib.
Not a fit: Patients who have received any systemic anti-cancer therapies within 12 months prior to dacomitinib treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the safety and effectiveness of dacomitinib for patients with advanced lung cancer.
How similar studies have performed: While this study focuses on patient experiences with dacomitinib, similar studies on EGFR-targeted therapies have shown promising results in treating lung cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Evidence of histologically or cytologically confirmed diagnosis of advanced NSCLC with EGFR-activating mutations detected by an appropriate test * Patients who were treated with dacomitinib as first-line treatment for advanced NSCLC during 01 October 2020 to 31 December 2022. * Age ≥18 years old * Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Exclusion Criteria: * Patients who have been treated with any systemic anti-cancer therapies within 12 months prior to dacomitinib treatment.
Where this trial is running
Taipei
- Tri-Service General Hospital — Taipei, Taiwan (Recruiting)
Study contacts
- Study coordinator: Pfizer CT.gov Call Center
- Email: ClinicalTrials.gov_Inquiries@pfizer.com
- Phone: 1-800-718-1021
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.